Methods for treating huntington's disease

(canceled)

A compound selected from the group consisting of:

• N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine, and
• N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine;
• wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

(canceled)

A compound salt selected from the group consisting of:

• N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride, and
• N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride;
• wherein a form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

10-11. (canceled)

The method of claim 19, wherein the effective amount of the compound, or form thereof, is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.

(canceled)

The method of claim 20, wherein the effective amount of the compound, or form thereof, is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.

(canceled)

The method of claim 21, wherein the effective amount of the compound, or form thereof, is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.

(canceled)